首页> 外文期刊>Journal of Neuroimmunology: Official Bulletin of the Research Committee on Neuroimmunology of the World Federation of Neurology >Labeling of dopamine D3 and D4 receptor subtypes in human peripheral blood lymphocytes with (3H)7-OH-DPAT: a combined radioligand binding assay and immunochemical study.
【24h】

Labeling of dopamine D3 and D4 receptor subtypes in human peripheral blood lymphocytes with (3H)7-OH-DPAT: a combined radioligand binding assay and immunochemical study.

机译:(3H)7-OH-DPAT标记人外周血淋巴细胞中的多巴胺D3和D4受体亚型:放射性配体结合测定和免疫化学研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Molecular biology studies have demonstrated that human peripheral blood lymphocytes express dopamine D2-like receptors belonging to the D3 and D4 receptor subtypes, whereas the characterization of these receptors using radioligand binding assay techniques provided conflicting results. The preferential dopamine D3 receptor agonist [3H]7-hydroxy-N, N-di-n-propyl-2-aminotetralin ([3H]7-OH-DPAT) was used recently for labeling lymphocyte dopamine D3 receptor. However, the selectivity of this compound for the D3 receptor was questioned. In this study we have investigated human peripheral blood lymphocyte dopamine receptor subtypes labeled by [3H]7-OH-DPAT using a conventional radioligand binding assay technique and antibodies against dopamine D2-like receptor subtypes. [3H]7-OH-DPAT was specifically bound to intact human peripheral blood lymphocytes with a dissociation constant (Kd) value of 0.32 + 0.03 nM and a maximum density of binding sites (Bmax) of 18.2 + 0.8 fmol/2 x 10(6) cells. [3H]7-OH-DPAT binding was unaffected by antibodies against dopamine D2 and D2S receptors. Anti-dopamine D3 and D4 receptor antibodies reduced [3H]7-OH-DPAT binding by about 53% and 32% respectively. Combination of anti D3 and D4 receptor antibodies reduced remarkably [3H]7-OH-DPAT binding. The above results suggest that the dopamine receptor agonist [3H]7-OH-DPAT labels dopamine D3 and D4 receptor subtypes in human peripheral blood lymphocytes. The use of antibodies raised against dopamine receptor subtypes in combination with radioligand binding assay may contribute to define receptor subtypes expressed by human peripheral blood lymphocytes in health and disease.
机译:分子生物学研究表明,人外周血淋巴细胞表达属于D3和D4受体亚型的多巴胺D2样受体,而使用放射性配体结合测定技术对这些受体的表征提供了相互矛盾的结果。最近,优先使用多巴胺D3受体激动剂[3H] 7-羟基-N,N-二正丙基-2-氨基四氢萘([3H] 7-OH-DPAT)标记淋巴细胞多巴胺D3受体。但是,该化合物对D3受体的选择性受到质疑。在这项研究中,我们使用常规的放射性配体结合测定技术和针对多巴胺D2样受体亚型的抗体,研究了由[3H] 7-OH-DPAT标记的人外周血淋巴细胞多巴胺受体亚型。 [3H] 7-OH-DPAT特异性结合至完整的人外周血淋巴细胞,其解离常数(Kd)值为0.32 + 0.03 nM,最大结合位点密度(Bmax)为18.2 + 0.8 fmol / 2 x 10( 6)细胞。 [3H] 7-OH-DPAT结合不受多巴胺D2和D2S受体抗体的影响。抗多巴胺D3和D4受体抗体分别将[3H] 7-OH-DPAT结合降低了约53%和32%。抗D3和D4受体抗体的组合显着降低了[3H] 7-OH-DPAT结合。以上结果表明,多巴胺受体激动剂[3H] 7-OH-DPAT标记人外周血淋巴细胞中的多巴胺D3和D4受体亚型。将针对多巴胺受体亚型产生的抗体与放射性配体结合测定结合使用,可能有助于确定人类外周血淋巴细胞在健康和疾病中表达的受体亚型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号